Key points
- Next-generation sequencing (NGS) reads millions of short DNA fragments at the same time, which is why it is also called massively parallel sequencing.
- It replaced Sanger sequencing, the chain-termination method published in 1977, for most large-scale work.
- Short-read NGS is highly accurate and inexpensive per base. Long-read technologies read much longer stretches and handle repetitive DNA better.
- In cancer care, NGS tumor panels test many genes at once to find mutations that match targeted drugs.
- NGS is also used to measure RNA (RNA-seq), find DNA from tumors in blood, and track how drugs change gene activity.
For decades, reading DNA was slow and expensive. Next-generation sequencing (NGS) changed that by reading millions of DNA fragments at once. It is the technology behind most modern genomics, from population studies of hundreds of thousands of people to the tumor tests that decide which cancer drug a patient receives.
Before NGS: Sanger sequencing
In 1977, Frederick Sanger and colleagues published a method for reading DNA using chain-terminating building blocks. When a DNA strand is copied in the presence of modified bases that stop copying, the result is a set of fragments that each end at a known base. Sorting the fragments by length reveals the sequence.
Sanger sequencing is highly accurate and is still used to confirm individual variants. It reads one DNA fragment per reaction, however, so sequencing a whole genome this way, as the Human Genome Project did, took more than a decade of international effort.
How NGS works
NGS keeps the basic idea of reading DNA by copying it, but does so for millions of fragments simultaneously. The most widely used approach, short-read sequencing by synthesis, works roughly like this:
- Library preparation. DNA is cut into short fragments, and small adapter sequences are attached to each end.
- Amplification. Each fragment is copied many times in a fixed spot on a glass surface, creating millions of clusters of identical copies.
- Sequencing. The strands are copied one base at a time using bases tagged with fluorescent labels. After each addition, a camera records the color at every cluster, revealing which base was added.
- Base calling. Software converts the series of images into DNA sequences, called reads.
- Analysis. The reads are aligned to a reference genome and compared with it to identify variants. See What Is Bioinformatics?
Each read is short, typically a few hundred bases, but the sheer number of reads covers the whole target many times over. That coverage, or depth, lets software distinguish true variants from occasional reading errors.
Short reads versus long reads
| Short-read sequencing | Long-read sequencing | |
|---|---|---|
| Read length | Typically 100–300 bases | Thousands to hundreds of thousands of bases |
| Strengths | Very high accuracy, very high throughput, low cost per base | Spans repetitive regions and large structural variants; can read DNA modifications directly |
| Limitations | Struggles with repetitive regions and large rearrangements | Historically lower accuracy and higher cost, though both have improved |
The two are complementary. The first complete, gap-free human genome sequence, published in 2022, relied on long reads to resolve the repetitive regions that short reads could not.
What NGS is used for
Cancer tumor profiling
NGS panels can test dozens to hundreds of cancer-related genes in a single tumor sample, looking for mutations that match available targeted drugs. Some NGS-based tests are approved by the FDA as companion diagnostics, meaning they are used to identify which patients are eligible for a specific drug. The FDA lists them alongside other companion diagnostic devices. See What Is Precision Medicine?
Rare-disease diagnosis
Whole genome and whole exome sequencing, both NGS-based, are now used to search for the genetic cause of rare diseases.
Measuring RNA
RNA sequencing (RNA-seq) converts RNA into DNA and sequences it, measuring which genes are active and how strongly. A 2009 review in Nature Reviews Genetics described RNA-seq as offering far more precise measurement of transcript levels than earlier methods. See What Is Transcriptomics?
Liquid biopsy
Tumors shed small amounts of DNA into the bloodstream. Sensitive NGS methods can detect this circulating tumor DNA in a blood sample, which can be used to profile a tumor without a tissue biopsy, or to monitor how a cancer responds to treatment.
Drug research
In drug development, NGS is used to sequence patients' tumors or genomes in clinical trials, to identify which genetic features predict response, and to measure how a drug changes gene activity in cells.
Accuracy and limitations
- Errors. Every technology makes reading errors. High coverage reduces their impact, and important clinical findings are often confirmed with a second method.
- Hard-to-sequence regions. Repetitive and highly similar regions remain challenging, particularly for short reads.
- Sample quality. Tumor samples, especially preserved tissue, can contain damaged DNA that complicates analysis.
- Interpretation. Sequencing produces data quickly. Deciding what a variant means remains slow, expert work.
Sources
- National Human Genome Research Institute. DNA Sequencing Fact Sheet.Regulator
- Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences USA. 1977;74(12):5463–5467.Peer-reviewed
- Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nature Reviews Genetics. 2009;10(1):57–63.Peer-reviewed
- Nurk S, et al. The complete sequence of a human genome. Science. 2022;376(6588):44–53.Peer-reviewed
- U.S. Food and Drug Administration. List of Cleared or Approved Companion Diagnostic Devices.Regulator
This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.